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httpicense.Abstract This work describes the stability-indicating determination of the H2-receptor antagonist
nizatidine in its bulk and capsules dosage form using high performance liquid chromatography cou-
pled with diode array detector (HPLC-DAD). The developed method involved the use of Thermo
Hypersil BDS-C8 (4.6 · 250 mm, 5 lm particle size) column and a mobile phase composed of
0.05 M phosphoric acid and acetonitrile (50:50, v/v). The mobile phase was pumped at a ﬂow rate
of 1 mL/min. Quantiﬁcation of nizatidine was based on measuring its peak area at 320 nm. The
retention time for nizatidine was about 3.61 min. The reliability and analytical performance of
the proposed HPLC procedure were statistically validated with respect to linearity, range, precision,
accuracy, speciﬁcity, robustness, detection and quantiﬁcation limits. Calibration curve of nizatidine
was linear in the range of 5–50 lg/mL with correlation coefﬁcient >0.9999. The drug was subjected
to forced-degradation conditions of acidic and basic hydrolysis, oxidation, dry heat and UV pho-
tolysis where it showed considerable degradation in basic and oxidative conditions. The proposed
method proved to be speciﬁc and stability-indicating by resolution of the drug from its forced-
degradation products. The validated HPLC method was applied to the analysis of nizatidine in
capsules dosage form where it was quantiﬁed with recoveries not less than 98.2%. Assay results
were statistically compared to USP 2011 pharmacopeial method where no signiﬁcant difference
was observed between the proposed and reference methods.
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Nizatidine (NZ) (Fig. 1) chemically known as N-[2-[[[2-
[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N0-methyl-
2-nitro-1,1-ethenediamine, is a histamine H2-antagonist. It
inhibits the actions of histamine mediated by H2-receptors
such as gastric acid secretion and pepsin output. It is used
where the inhibition of gastric acid secretion may be beneﬁcial,aculty of Pharmacy, Cairo University.
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Figure 1 Chemical structure of nizatidine (NZ).
186 T.S. Belal et al.as in peptic ulcer disease including stress ulceration, gastro-
esophageal reﬂux, dyspepsia, pathological hypersecretory
states such as the Zollinger–Ellison syndrome and in patients
at risk of acid aspiration during general anesthesia.1
NZ is an ofﬁcial drug in both the British Pharmacopoeia
(BP 2010)2 and the Unites States Pharmacopeia (USP 2011)3
where HPLC procedures are described for the assay of the
bulk powder and dosage forms (capsules and intravenous infu-
sion). The analytical proﬁle4 of NZ provides a survey for the
reported methods of analysis during the eighties of the last cen-
tury. Moreover, the quantiﬁcation of NZ in its pharmaceutical
formulations and/or biological samples was addressed in sev-
eral reports. Analytical methodology in these reports involved
the use of potentiometric titration with palladium (II) chlo-
ride,5 oxidimetric titration with N-bromosuccinimide,6 DC
and differential-pulse polarography,7 cathodic stripping vol-
tammetry on hanging mercury drop electrode8 and several col-
or-producing spectrophotometric methods employing various
reactions and reagents.6,8–12 Recently, a sensitive ﬂuorescence
probe for determination of NZ in tablets and biological ﬂuids
was presented.13 Also, the scientiﬁc literature showed the use
of separation techniques such as capillary zone electrophoresis
for separation and simultaneous determination of some H2
receptor antagonists including NZ,14,15 HPLC-tandem mass
spectrometry (LC–MS–MS) for detection of eight anti-ulcer
drugs simultaneously in horse urine16 and several HPLC-UV
detection methods which were directed for NZ determination
in commercial products17 or in human plasma and urine sam-
ples.18–20
A review of the literature reveals a few number of reported
stability indicating assay methods for NZ. Spectrophotometric
stability indicating assay methods for the determination of in-
tact NZ in the presence of its degradation products were devel-
oped.21,22 These methods involved the formation of colored
products between NZ and bromophenol blue21 or 3-methyl-
2-benzothiazolinone hydrazone (MBTH)22 followed by mea-
suring peak heights of their ﬁrst derivative spectra. Stability
indicating determination of NZ in the presence of its oxidative
degradation product (sulfoxide derivative) was carried out
using derivative and derivative ratio spectrophotometry as well
as TLC densitometry.23 Recently, RP-HPLC was adopted for
the stability indicating determination of NZ in the presence of
its impurities and forced degradation products.24 Finally, a
RP-UPLC method was reported for the stability indicating as-
say of oral liquid pharmaceutical formulation containing NZ,
methylparaben and propylparaben.25
The aim of this work is the development, validation and
application of a simple, rapid, selective and reliable HPLC-
DAD method for the analysis of NZ in bulk powder and in
capsules dosage form. The method was thoroughly tested for
its speciﬁcity and stability-indicating properties by resolution
of the parent drug from its forced hydrolytic, oxidative, dry
heat and photolytic degradation products.2. Experimental
2.1. Instrumentation
The HPLC-DAD system consisted of Agilent 1200 series (Agi-
lent Technologies, Santa Clara, CA, USA) (quaternary pump,
vacuum degasser and diode array, autosampler and thermo-
stated column compartment) connected to a computer loaded
with Agilent ChemStation software. Columns used in the study
were Thermo Hypersil BDS-C8 (4.6 · 250 mm, 5 lm particle
size), Thermo Hypersil BDS-C18 (4.6 · 250 mm, 5 lm particle
size) and Zorbax Eclipse XDB–C18 (4.6 · 150 mm, 5 lm par-
ticle size). Filtration was done using cellulose nitrate mem-
brane ﬁlters (0.45 lm pore size) (Sartorius Stedim Biotech
GmbH, Goettingen, Germany) with the aid of VALUE
VG215 2-stage vaccum pump (Zhejiang, China).
2.2. Materials and chemicals
Authentic sample of Nizatidine (NZ) was kindly provided by
the Alexandria Company for Pharmaceuticals and Chemical
Industries, Alexandria, Egypt, and was certiﬁed to contain
99.5% NZ. Analytical grade of orthophosphoric acid, sodium
hydroxide, hydrochloric acid, 30% hydrogen peroxide and
high purity distilled water were used. HPLC grade acetonitrile
and methanol (LAB-SCAN Analytical Sciences, Poland) were
used. Pharmaceutical formulation assayed in the study was
Ulcfree capsules (EVA Pharma for Pharmaceuticals & Med-
ical Appliances, Giza, Egypt, BN. 905656) labeled to contain
150 mg of NZ per capsule, and it was purchased from the local
market.
2.3. General procedure
The optimal composition of the mobile phase was determined
to be acetonitrile and 0.05 M phosphoric acid (50:50, v/v). The
mobile phase was pumped isocratically at a ﬂow rate of 1 mL/
min. The injection volume was 20 lL. The eluant was moni-
tored by the diode array detector from 190 to 400 nm, and
chromatograms were recorded at 210, 254 and 320 nm. All
determinations were performed at 25 C.
NZ stock standard solution (1000 lg/mL) was prepared in
HPLC-grade methanol. The prepared stock solution was
stored and refrigerated at 4 C. The working solutions were
prepared by the dilution of NZ stock standard solution
with the mobile phase to reach the concentration range of
5–50 lg/mL. Triplicate 20 lL injections were made for each
concentration and chromatographed under the previously
described LC conditions. The peak areas at 320 nm were
plotted against the corresponding concentrations to construct
the calibration graph.
2.4. Assay of capsules
The contents of 10 Ulcfree capsules were accurately weighed,
mixed, ﬁnely powdered and the average weight per capsule was
determined. An accurate weight of the ﬁnely powdered sample
equivalent to 50 mg of NZ was extracted into 25 mL methanol
(HPLC grade) with the aid of sonication for 30 min then ﬁl-
tered into a 50 mL-volumetric ﬂask. The residue was washed
HPLC-DAD stability indicating determination of nizatidine in bulk and capsules dosage form 187with 2 · 10 mL portions of methanol and washings were added
to the ﬁltrate. The ﬁltrate was diluted to volume with methanol
to reach a ﬁnal concentration of 1000 lg/mL for NZ (stock
sample solution). For the prepared stock sample solution, fur-
ther dilutions in the mobile phase were made to obtain sample
solutions of ﬁnal concentrations within the linearity range of
5–50 lg/mL, and the general procedure was then followed.
Recovery values were calculated from similarly treated stan-
dard solutions. For standard addition assay, sample solutions
were spiked with aliquots of stock standard NZ to obtain total
concentrations within the previously speciﬁed range then trea-
ted as under general procedure. Recovered concentrations
were calculated by comparing the analyte response with the
increment response attained after the addition of the standard.
2.5. Preparation of forced-degradation solutions
For the acid and base forced degradation solutions, volumes of
1 mL of NZ stock standard solution were transferred into 50-
mL volumetric ﬂasks. Volumes of 2-mL of 1 M HCl or 1 M
NaOH were added and the mixtures were kept at room tem-
perature for 24 h. Similar reaction mixtures were prepared in
test tubes and were placed in a water-bath at 80 C for 2 h
(for the acid degradation solution) and 30 min (for the base
degradation solution). During heating, volume loss was com-
pensated with methanol. After the speciﬁed time intervals,
the mixtures in the test tubes were quantitatively transferred
into 50-mL volumetric ﬂasks. All solutions were neutralized
with appropriate volumes of 1 M NaOH or 1 M HCl and di-
luted to volume with mobile phase to reach ﬁnal concentra-
tions of 20 lg/mL NZ.
For the oxidative degradation solution, a volume of 1 mL
of NZ stock standard solution was transferred into a 50-mL
volumetric ﬂask. A volume of ½ mL of H2O2 6% (prepared
by dilution of hydrogen peroxide 30% with water) was added
and the mixture was kept at room temperature for 24 h. An-
other similar reaction mixture was prepared in a test tube
and was placed in a water-bath at 80 C for 30 min. After
the speciﬁed time interval, the mixture in the test tube was
quantitatively transferred into a 50-mL volumetric ﬂask, and
then both solutions were diluted to volume with mobile phase
to reach ﬁnal concentrations of 20 lg/mL NZ.
For the UV photolytic and dry heat degradations, amounts
of NZ powder (50 mg) were subjected to UV irradiation at
254 nm for 3 h or kept in an oven at 100 C for 24 h. After
the speciﬁed time intervals, each powder was dissolved in
methanol, and aliquots of these methanolic stocks were diluted
with the mobile phase to reach ﬁnal concentrations of 20 lg/
mL NZ.Figure 2 Typical HPLC chromatogram of a 20-lL injection of
20 lg/mL NZ at 320 nm.3. Results and discussion
3.1. Optimization of chromatographic conditions
A stability-indicating HPLC-DAD method was developed to
provide a simple, rapid and reliable quality control analysis
of NZ in capsules. The most important aspect in LC method
development is the achievement of sufﬁcient resolution with
acceptable peak symmetry in a reasonable analysis time. To
achieve this goal, several experiments were carried out in order
to optimize both the stationary and mobile phases. For thestationary phase, several reversed phase C8 and C18 columns
were tested. The best resolution of NZ from its degradation
products and best NZ peak shape were attained by using Ther-
mo Hypersil BDS-C8 (4.6 · 250 mm, 5 lm) column, and hence
it was used in this study. Several mobile phases were tried
using various proportions of different aqueous phases and or-
ganic modiﬁers. Decreasing the acetonitrile content in the mo-
bile phase led to longer retention times and excessive peak
tailing. While increasing acetonitrile content yielded a NZ
peak that was very close to the solvent peak, in addition to
insufﬁcient resolution of the parent drug peak from some of
its degradation products peaks. Methanol was tried as an or-
ganic modiﬁer and different aqueous phases (water, acetate
buffer) were examined. In these trials, chromatograms showed
broad asymmetric NZ peaks and/or increased retention times
and, consequently, fewer theoretical plates for NZ. The best
chromatogram (Fig. 2) was obtained using a mobile phase con-
sisting of acetonitrile and 0.05 M phosphoric acid (50:50, v/v)
pumped isocratically at a ﬂow rate of 1.0 mL/min. The pro-
posed method has the advantage of using such simple mobile
phase where there is no need for the preparation of buffer or
adjustment of pH.
Diode array detection enhances the power of HPLC and is
an elegant option for assessing method speciﬁcity by monitor-
ing the recorded spectra during peak elution. Quantiﬁcation
was achieved using diode array detection based on peak area
measurement. NZ exhibits considerable absorption over the
range of 200–350 nm with a prominent maximum at 320 nm,
therefore it was selected for NZ quantiﬁcation. In addition,
other wavelengths such as 210 and 254 nm were found suitable
for recording chromatograms of the degradation solutions be-
cause some of the degradation products did not show enough
absorption at 320 nm. Table 1 assembles the optimized chro-
matographic conditions for this study. The previously de-
scribed chromatographic conditions showed well deﬁned NZ
peak at 3.608 ± 0.033 min. Column performance (apparent
efﬁciency) can be expressed by the number of theoretical plates
(N) which equals 4380.
3.2. Stability indicating aspects
Forced degradation experiments were carried out on standard
NZ in order to produce the possible relevant degradation
products and test their chromatographic behavior using the
developed method. Hydrolytic, using strong acidic (1 M
HCl) and strong basic (1 M NaOH) media, oxidative (6%
H2O2), photolytic and dry heat degradation experiments were
Table 1 Optimized chromatographic conditions.
Column Thermo Hypersil reversed phase
BDS-C8 (4.6 · 250 mm, 5 lm particle
size)
Mobile phase Isocratic elution of 0.05 M ortho-
phosphoric acid and acetonitrile
(50:50, v/v)
Wavelength (nm) 320 nm (for quantiﬁcation of NZ)
210, 254 and 320 nm (for recording of
degradation chromatograms)
Flow rate (mL/min) 1.0 mL/min
Temperature 25 C
Figure 3 HPLC chromatogram of 20 lg/mL NZ after exposure
to acid degradation with 1 M HCl/80 C for 2 h.
Figure 4 HPLC chromatogram of 20 lg/mL NZ after exposure
to alkaline degradation with 1 M NaOH/80 C for 30 min.
Figure 5 HPLC chromatogram of 20 lg/mL NZ after exposure
to oxidative degradation with 6% H2O2/80 C for 30 min.
Figure 6 HPLC chromatogram of 20 lg/mL NZ after exposure
to UV irradiation at 254 nm for 3 h.
188 T.S. Belal et al.conducted, and the resulting chromatograms were compared
with that obtained from standard untreated solution of the
drug (Fig. 2).
Hydrolytic and oxidative degradation studies on NZ were
conducted either at room temperature or with the aid of heat-
ing. In strong acidic medium, no degradation of NZ was no-
ticed. The drug peak appeared at its speciﬁc retention time
with area identical to that of standard of the same concentra-
tion, additionally, the chromatograms of NZ after exposure to
forced acidic conditions did not show any extra peaks. Fig. 3
shows the intact NZ peak after heating at 80 C for 2 hrs with
1 M HCl. On the other hand, alkaline degradation with 1 M
NaOH at room temperature caused about 6% reduction in
the peak area of NZ, while about 26% decrease in NZ peak
area was observed after heating at 80 C for 30 min. A well-
resolved major degradation peak can be seen in the chromato-
gram at a retention time of 2.34 min (Rs= 7.69 between NZ
peak and the alkaline degradation peak) (Fig. 4).
Oxidative H2O2 degradation at room temperature revealed
quite an intact NZ peak as indicated from its peak area com-
pared to standard of the same concentration. The situation
was much different upon heating at 80 C for 30 min where
a remaining NZ peak eluted with about 40% of the expected
area, and a degradation product peak appeared at 3.20 min
(Rs= 2.43). The sulfur atom in the side chain of NZ is suscep-
tible to oxidation, accordingly, the oxidative degradation
product is most probably the S-oxide derivative of NZ (nizat-
idine sulfoxide).23 Fig. 5 illustrates the chromatogram of NZ
after heating with 6% hydrogen peroxide at 80 C for
30 min. No degradation was observed after exposure of NZ
powder to UV photolytic or dry heat forced degradationconditions. After the speciﬁed time intervals, solutions were
prepared from the stressed powder samples. The NZ peak ap-
peared at its speciﬁc retention time with area identical to that
of a standard of the same concentration, additionally, no extra
peaks were observed in the chromatograms (Figs 6 and 7).
In all these forced degradation experiments, NZ was suc-
cessfully separated from all the degradation products as con-
ﬁrmed by the resolution values calculated for each
chromatogram (Rs> 1.5). Also the identity and purity of
NZ were conﬁrmed by the diode array detector (DAD), and
no signs of co-elution from any of the degradation products
were detected.
Figure 7 HPLC chromatogram of 20 lg/mL NZ after exposure
to dry heat degradation at 100 C for 24 h.
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3.3.1. Linearity and concentration range
Under the optimal experimental chromatographic conditions,
linear relationship exists between the integrated peak area
and the corresponding concentration of NZ. The performance
data and statistical parameters including linear regression
equation, concentration range, correlation coefﬁcient (r) and
other statistical parameters such as the standard deviation of
the intercept (Sa), the slope (Sb) and standard deviation of
residuals (Sy/x) are listed in Table 2. Regression analysis for
the calibration curve showed good linear relationship over
the concentration range of 5–50 lg/mL as judged by the corre-
lation coefﬁcient value (r= 0.99993), the RSD% of the slope
which did not exceed 1% and the y-intercept, a, which was less
than 2% of the response for the target value of the analyte.26
3.3.2. Detection and quantiﬁcation limits
According to the pharmacopeial recommendations3 and the
ICHguidelines on validation of analytical procedures,27 the lim-
it of detection (LOD) is deﬁned as the concentration of the ana-
lyte which has a signal-to-noise ratio of 3:1. For the limit of
quantiﬁcation (LOQ), the ratio considered is 10:1. The LOD
and LOQ values of NZwere calculated using the signal-to-noiseTable 2 Analytical parameters for the determination of NZ
using the proposed HPLC-DAD method.
Parameter Value
Linearity range (lg/mL) 5–50
Intercept (a) 7.61
% y-intercepta
(Peak area at 100% target concentration)
0.87 (874.6)
Slope (b) 44.11
RSD% of slope 0.61
Correlation coeﬃcient (r) 0.999925
Sa
b 8.17
Sb
c 0.27
Sy/x
d 10.50
LOD (lg/mL) 0.31
LOQ (lg/mL) 1.03
a % y-intercept = yinterceptpeak area at 100% target concentration 100
b Sa: standard deviation of intercept.
c Sb: standard deviation of slope.
d Sy/x: standard deviation of residuals (standard error of
estimate).ratio method and are given in Table 2. Both LOD and LOQ val-
ues conﬁrm the sensitivity of the proposed HPLC procedure.
3.3.3. Accuracy and precision
The within-day (intra-day) precision and accuracy for the pro-
posed method were studied at three concentration levels (10,
20 and 40 lg/mL) using three replicate determinations for each
concentration within one day. Similarly, the between-day (in-
ter-day) precision and accuracy were tested by analyzing the
same three concentrations using three replicate determinations
repeated for three days. Recovered concentrations were calcu-
lated using the corresponding regression equation and they
were satisfactory. The percentage relative standard deviation
(RSD%) and percentage relative error (Er%) were less than
1.5% proving the high repeatability and accuracy of the devel-
oped method for the estimation of NZ in bulk form (Table 3).
3.3.4. Robustness
The robustness of an analytical procedure is a measure of its capa-
bility to remain unaffected by small but deliberate variations in
methodparameters andprovides an indicationof its reliability dur-
ing normal usage.3,27 Robustness was examined by making small
changes in acetonitrile content in the mobile phase (±2%), ﬂow
rate (±0.05 mL/min), column temperature (±2 C) or working
wavelength (±2 nm) and examining the results. These variations
did not have any signiﬁcant effect on the measured response (peak
area) or retention time ofNZ.Table 4 shows the effects of the stud-
iedvariationson the retention timeandpeakareaofNZ.Addition-
ally, theseminor experimental changesdidnot affect the separation
of NZ from its degradation products.
3.3.5. Speciﬁcity and selectivity
Speciﬁcity of the method was assessed by comparing the chro-
matograms obtained from standard solution with the chro-
matograms obtained from capsules sample solution. As the
retention time of the standard drug and the retention time of
the drug in capsule test solution were the same, so the method
was speciﬁc. On the other hand, the use of photodiode array
detector allowed conﬁrming the selectivity of the method by
comparison with the reference drug spectrum, hence the meth-
od proved to be selective in separation of the investigated drug.
Selectivity was also demonstrated by the separation of NZ
from forced degradation products and formulation additives.
3.3.6. Stability of solutions
The stability of the analyte’s working solutions in the mobile
phase was examined, and no chromatographic changes were
observed within 5 h at room temperature. Also, the stock solu-
tions prepared in HPLC-grade methanol were stable for at
least one week when stored and refrigerated at 4 C.
3.4. Assay of capsules
The developed stability-indicating HPLC procedure was ap-
plied to the assay of NZ in the pharmaceutical formulation
available in the local market (Ulcfree capsules). The active
ingredient eluted at its speciﬁc retention time, and no interfering
peaks were observed in the chromatograms of NZ capsules. The
diode-array detection enables peak purity veriﬁcation where no
signs of co-elution from any of the inactive components were
Table 3 Accuracy and precision for the analysis of NZ in bulk form using the proposed HPLC-DAD method.
Nominal value
(lg/mL)
Found ± SDa (lg/mL) RSD(%)b Er (%)
c
Within-day 10 9.93 ± 0.07 0.71 0.70
20 19.74 ± 0.16 0.81 1.30
40 40.01 ± 0.23 0.58 0.03
Between-day 10 9.96 ± 0.11 1.10 0.40
20 19.98 ± 0.27 1.35 0.10
40 40.19 ± 0.34 0.85 0.48
a Mean ± standard deviation for three determinations.
b % Relative standard deviation.
c % Relative error.
Table 4 Robustness of the proposed HPLC-DAD method.
Chromatographic
parameter
NZ peak area NZ retention
time (min)
Acetonitrile percentage in the mobile phase
48 843 3.81
50 831 3.74
52 820 3.70
RSD% 1.38 1.49
Flow rate (mL/min)
0.95 868 3.95
1.00 831 3.74
1.05 803 3.58
RSD% 3.91 4.94
Column temperature (C)
23 835 3.76
25 831 3.74
27 823 3.71
RSD% 0.74 0.67
Working wavelength (nm)
318 817
320 831
322 828
RSD% 0.89
190 T.S. Belal et al.detected. Recoveries were calculated using both external stan-
dard and standard addition methods. The assay results revealed
satisfactory accuracy and precision as indicated from % recov-
ery, SD and RSD% values (Table 5).
Furthermore, the USP reference HPLC method3 was ap-
plied for the estimation of NZ in its commercial product.
The pharmacopeial method is based on the analysis of NZTable 5 Analysis of NZ in its pharmaceutical prepara
DAD method and the reference method.
Method results External standard
%Recovery ± SDa 99.24 ± 0.552
RSD%b 0.556
t 1.78
F 1.85
Theoretical values for t and F at P= 0.05 are 2.31 and 6.39
a Mean ± standard deviation for ﬁve determinations.
b % Relative standard deviation.using a RP-C18 column (4.6 mm · 15 cm, 5 lm particle size),
the mobile phase consisted of methanol and 0.1 M ammonium
acetate adjusted to pH 7.5 with acetic acid (24:76, v/v) and UV
detection at 230 nm. According to these conditions, the inter-
nal standard (phenol) and NZ eluted at retention times 8.74
and 11.17 min respectively. Recovery data obtained from the
proposed HPLC method were statistically compared with
those of the reference method using the Student’s t- and the
variance ratio F-tests. In both tests, the calculated values did
not exceed the theoretical ones at the 95% conﬁdence level
which indicated that there were no signiﬁcant differences be-
tween the recoveries obtained from the developed method
and those of the reference method (Table 5). It is evident from
these results that the proposed method is applicable to the as-
say of NZ capsules with satisfactory level of selectivity, accu-
racy and precision.
4. Conclusion
A simple, rapid and selective HPLC-DAD procedure was
developed for the assay of NZ in bulk form and in capsules.
The analyte was quantiﬁed using a RP-C8 column in a short
run time; consequently, the developed method can be consid-
ered cost and time-effective. The proposed method is sensitive
enough to determine a concentration down to 5 lg/mL NZ.
Moreover, the method was extended to study the degradation
behavior of NZ under different forced degradation conditions.
Few reports were published concerning the forced degradation
of NZ and/or its stability indicating determination. Obviously,
the described HPLC method offers selectivity advantage
over the spectrophotometric non-separation methods describ-
ing the stability indicating estimation of NZ.21–23 Also, the
proposed HPLC method is more reliable than the stabilitytion (Ulcfree capsules) using the proposed HPLC-
Reference method3 Standard addition
99.78 ± 0.406 99.08 ± 0.791
0.407 0.798
, respectively.
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plied for the assay of NZ in the presence of its oxidative deg-
radation product.23 The method holds a challenge and is
advantageously compared with the other reported liquid chro-
matographic methods,2,3,18,25,26 brieﬂy mentioning the follow-
ing points: short run time (5 min), simple since no internal
standard is required and the mobile phase is pumped isocrati-
cally while multi-step gradient elutions are applied in other
procedures24,25 and ﬁnally the developed method made use
of the diode array detector as a tool for peak identity and pur-
ity conﬁrmation; however, it can be adapted to conventional
HPLC with UV detection which is the most popular in quality
control laboratories.5. Conﬂict of interest
None.
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